RPg Family Wealth Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

RPg Family Wealth Advisory’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,826	Closed	-$6.12M	–	106
2024 Q2	$6.12M	Sell	5,826 -21	-0.4%	-$20.4K	2.01%	20
2024 Q1	$5.63M	Buy	5,847 +79	+1%	+$75.1K	1.78%	25
2023 Q4	$5.07M	Buy	5,768 +100	+2%	+$82.3K	1.87%	20
2023 Q3	$4.66M	Buy	+5,668	New	+$4.45M	1.92%	20

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RPg Family Wealth Advisory's REGN Position: Q3 2024 in Review

RPg Family Wealth Advisory sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 5,826 shares — an estimated $6.12M sold.

RPg Family Wealth Advisory first reported a position in REGN in Q3 2023 and held it in 4 quarters. The position peaked at $6.12M in Q2 2024. 1,389 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

RPg Family Wealth Advisory reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
RPg Family Wealth Advisory sold 5,826 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $6.12M.
RPg Family Wealth Advisory first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 4 quarters.
RPg Family Wealth Advisory's Regeneron Pharmaceuticals position peaked at $6.12M in Q2 2024.
1,389 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on RPg Family Wealth Advisory's 13F filing for Q3 2024, filed 5 Nov 2024.